Gastroenterology · Crohn's DiseaseTrial Updateclinicalmid-term

Janssen's Guselkumab Compared to Risankizumab in Crohn's Disease Study Initiated

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/7/2026, 12:31:03 PM

Assessment confidence: 66% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The initiation of this head-to-head trial between guselkumab and risankizumab is significant as it could reshape treatment guidelines and market dynamics in the Crohn's Disease therapeutic area. Monitoring the trial outcomes is essential for understanding competitive positioning and potential shifts in prescribing practices. Regulatory context from FDA (FDA AP — SKYRIZI (SUPPL)) supports the near-term read. Assessment grounded in 22 ranked evidence items (10 high-relevance).

Strategic Assessment

Portfolio teams should monitor trial outcomes closely as they may influence treatment guidelines and market positioning for both therapies. The strongest clinical anchor is A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease (ClinicalTrials.gov), entity match (janssen). In Gastroenterology · Crohn's Disease, 6 regulatory and 3 competitive items passed relevance filtering for Janssen.

Competitive Pressure

The most relevant competitive pressure comes from Phase III Trial of Afimkibart Shows Promise for Moderately to Severely Active Crohn's Disease (Humanexa Signals) — entity match (crohn s disease market). Secondary pressure from Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study. This head-to-head trial could provide critical insights into the relative effectiveness of two competing therapies in a key inflammatory bowel disease market.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — SKYRIZI (SUPPL) (FDA). Entity match (abbvie); Regulatory pathway relevance (bla). Relevant agencies in corpus: FDA, MHRA. Depending on the trial outcomes, there may be implications for label updates or new treatment guidelines that could affect regulatory submissions and approvals.

Key Risks

Elevated medium regulatory exposure for Janssen could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

The results of this trial could influence market share and revenue for both therapies, impacting sales strategies and competitive positioning in the inflammatory bowel disease market.
Portfolio teams should monitor trial outcomes closely as they may influence treatment guidelines and market positioning for both therapies.

What Would Change This Assessment

This becomes more urgent if Key milestones include interim results and final efficacy data from the trial.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — SKYRIZI (SUPPL)
FDAhigh relevance
Entity match (abbvie); Regulatory pathway relevance (bla)
FDA document
View source
FDA AP — SKYRIZI (SUPPL)
FDAhigh relevance
Entity match (abbvie); Regulatory pathway relevance (bla)
FDA document
View source
FDA Approves First Gene Therapy for Young Children with Sickle Cell Disease
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
Semaglutide (Wegovy) approved to treat form of liver disease
MHRAhigh relevance
Moderate corpus alignment
FDA document
View source
Lessons Learned from our Roundtable with Rare Disease Advocates
FDAhigh relevance
Moderate corpus alignment
FDA document
View source
Office of New Drugs Custom Medical Queries (OCMQs) for Safety Signal Detection in Clinical Trial Data - 06/23/2026
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
ClinicalTrials.govhigh relevance
Entity match (janssen)
FDA document
View source
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Merck)
FDA document
View source
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
KHENERFIN Study: A Trial to Evaluate the Efficacy and Safety of Sonlicromanol in Primary Mitochondrial Diseases
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Robotic Minimally Invasive Inguinal Hernia Repair Post-Market Clinical Study With the DEXTER Robotic System
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Effect of Participating in Study of Causes of Pregnancy Loss on Mental Health Outcomes: A Target Trial Emulation Using the COPL Cohort and Danish National Registries
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Phase III Trial of Afimkibart Shows Promise for Moderately to Severely Active Crohn's Disease
Humanexa Signalshigh relevance
Entity match (crohn s disease market)
Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study
Humanexa Signalsmedium relevance
Sponsor/company relevance (Roche)
Roche to present new Alzheimer’s data, including trontinemab and pTau217 blood test, at AAIC 2026
Humanexa Signalsmedium relevance
Sponsor/company relevance (Roche)

A phase 3, randomized study to evaluate the safety, tolerability, and immunogenicity of V116 in children and adolescents with increased risk of pneumococcal disease (STRIDE-13).
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Amino acid infusion and acute kidney injury after aortic surgery: a multicenter observational study with target trial emulation.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Elevated ESR2 and BRCA1 gene expression in adenomyosis associated with endometrial cancer: a pilot study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Cost-effectiveness analysis of apixaban compared with other oral anticoagulants for the treatment of non-valvular atrial fibrillation in Belgian healthcare setting.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of fecal microbiota transplantation and probiotics on the gut microbiome in antibiotic-treated septic patients: A pilot randomized controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Immunogenicity and safety of an investigational quadrivalent measles, mumps, rubella, and varicella vaccine in children aged 4-6 years: A phase II, randomized, multi-country trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Janssen
AbbVie
Guselkumab
Risankizumab
Crohn's Disease market

Commercial impact

medium

The results of this trial could influence market share and revenue for both therapies, impacting sales strategies and competitive positioning in the inflammatory bowel disease market.

Regulatory impact

medium

Depending on the trial outcomes, there may be implications for label updates or new treatment guidelines that could affect regulatory submissions and approvals.

What to watch

Key milestones include interim results and final efficacy data from the trial.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.